SCHEMBL26487595

SCHEMBL26487595

COc1ccc(C(=O)N2CCN(C(=O)c3ccc(Br)cc3)CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 3/20 0.73
KCNH2 Q12809 1/20 0.73
HPGD P15428 2/20 0.73
ALDH1A1 P00352 3/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA7 P43166 1/20 0.64
CA9 Q16790 1/20 0.64
CA14 Q9ULX7 1/20 0.64
MAPT P10636 2/20 0.64
MAPK1 P28482 2/20 0.64
MEN1 O00255 1/20 0.64
LMNA P02545 1/20 0.64
RAB9A P51151 1/20 0.64
KMT2A Q03164 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
RXFP1 Q9HBX9 1/20 0.64
GAA P10253 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20631562 0.91 HPGD (0.86) GPR183HPGDALDH1A1L3MBTL1CA12
SCHEMBL29259413 0.87 GPR183 (0.62) GPR183KCNH2HPGDALDH1A1L3MBTL1
SCHEMBL29259396 0.87 GPR183 (0.62) GPR183KCNH2HPGDALDH1A1L3MBTL1
SCHEMBL16598583 0.85 GPR183 (1.00) GPR183KCNH2
SCHEMBL16598585 0.85 GPR183 (1.00) GPR183KCNH2
SCHEMBL10053023 0.85 HPGD (0.75) GPR183HPGDALDH1A1L3MBTL1CA12
SCHEMBL2534411 0.84 HPGD (1.00) HPGDALDH1A1L3MBTL1CA12CA1
SCHEMBL2535536 0.83 HPGD (0.96) HPGDALDH1A1L3MBTL1CA12CA1
SCHEMBL26093881 0.83 GPR183 (0.93) GPR183KCNH2
SCHEMBL19479126 0.82 ALDH1A1 (0.83) HPGDALDH1A1L3MBTL1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034121-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) 2025-01-30 US claimed
EP-4419511-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS Nanjing Immunophage Biotech Co., Ltd (CN) 2024-08-28 EP claimed
CN-118201911-A Compounds and their use as GPR183 inhibitors 南京艾美斐生物医药科技有限公司 2024-06-14 CN claimed
WO-2023066190-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2023-04-27 WO claimed
WO-2023066190-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034121-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS GPR183, GPR180, GPR65 GPR183 1/4885KCNH2 2579/4885HPGD 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.